OS Therapies terminates $15M equity line; $4.2M raised, burn reduced

OS Therapies Inc

Terminated ELOC Purchase Agreement with Square Gate effective Aug 26, 2025; no outstanding borrowings or fees.
Recent warrant exercise exchange provided $4.2M gross proceeds to fund operations into mid-2026.
Projected monthly burn in H2 2025 significantly lower than H1 2025, completing Phase 2b and Phase 1b treatment phases.
Company focusing capital on advancing OST-HER2 toward approval and analyzing OST-504 prostate cancer data.

item 1.02item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.